Novo and existing investor AstraZeneca contributed to a round that will support Entasis Therapeutics' anti-infectives pipeline.
US-based anti-infective treatment developer Entasis Therapeutics closed a $50m series B round yesterday that included pharmaceutical companies Novo and AstraZeneca.
Life sciences-focused investment firm Clarus led the round, which also featured specialist investment firm Frazier Healthcare Partners and investment adviser Eventide Funds.
Entasis is working on drugs to combat drug-resistant bacterial infections, and the financing will be used to advance a pipeline of clinical and preclinical candidates. AstraZeneca spun the company out in February 2015 with $40m of funding to…